Taurolidine is an unlicensed product available as an intraperitoneal lavage (Taurolin®). It acts as an antibiotic and an anti-endotoxin with a broad spectrum of activity against Gram negative and positive bacteria and fungi. Taurolidine is active in vitro against P. aeruginosa and Burkholderia Cepacia Complex (Bcc) (Perry et al, 2002) but a four week randomised, double-blind, placebo controlled trial of 4mls nebulised taurolidine solution 2% versus saline solution in 20 adult patients with CF showed no in-vivo anti-Bcc activity (Ledson et al, 2002). Successful Bcc eradication has been reported in a non-CF patient (Ledson et al, 2000). Taurolidine may cause bronchospasm, cough or a mild ‘burning’ sensation in the throat. An initial test dose should be given. Care is advised in renal insufficiency.
• Taurolidine is active in vitro against P. aeruginosa and Bcc
• Taurolidine is an unlicensed product
Ledson MJ, Cowperthwaite C, Walshaw MJ, et al. Nebulised taurolidine and cepacia bronchiectasis. Thorax 2000; 55: 91-92. [PubMed]
Ledson MJ, Gallagher MJ, Robinson M, et al. A randomized double-blinded placebo-controlled crossover trial of nebulized taurolidine in adult cystic fibrosis patients infected with Burkholderia cepacia.J Aerosol Med. 2002;15(1):51-7. [PubMed]
Perry JD, Riley G, Johnston S, et al. Activity of disinfectants against Gram-negative bacilli isolated from patients undergoing lung transplantation for cystic fibrosis. J Heart Lung Transplant 2002; 21: 1230-1231. [PubMed]